346 related articles for article (PubMed ID: 16448441)
1. Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
Massoud W; Paparel P; Lopez JG; Perrin P; Daumont M; Ruffion A
Int J Urol; 2006 Jan; 13(1):87-8. PubMed ID: 16448441
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a pituitary adenoma following a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
Massoud W; Paparel P; Lopez JG; Perrin P; Daumont M; Ruffion A
Int J Urol; 2006 Mar; 13(3):303-4. PubMed ID: 16643633
[TBL] [Abstract][Full Text] [Related]
3. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.
Van Poppel H; Klotz L
Int J Urol; 2012 Jul; 19(7):594-601. PubMed ID: 22416801
[TBL] [Abstract][Full Text] [Related]
4. Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer.
Curry EA; Sweeney CJ
J Urol; 2002 Jul; 168(1):193. PubMed ID: 12050525
[No Abstract] [Full Text] [Related]
5. Pituitary apoplexy following gonadotropin-releasing hormone agonist administration with gonadotropin-secreting pituitary adenoma.
Sasagawa Y; Tachibana O; Nakagawa A; Koya D; Iizuka H
J Clin Neurosci; 2015 Mar; 22(3):601-3. PubMed ID: 25455737
[TBL] [Abstract][Full Text] [Related]
6. Implications of androgen-deprivation therapy in patients with prostate cancer: A case study.
Doyle-Lindrud S
Clin J Oncol Nurs; 2006 Oct; 10(5):565-6. PubMed ID: 17063610
[TBL] [Abstract][Full Text] [Related]
7. Gonadotropin releasing hormone analogue antiandrogen failure secondary to a pituitary adenoma.
Ogan K; Berger M; Ball R
J Urol; 1998 Aug; 160(2):497-8. PubMed ID: 9679910
[No Abstract] [Full Text] [Related]
8. Intracranial metastatic prostate carcinoma presenting as intermittent double vision.
Saito Y; Kondo Y; Shimizu H; Kunimoto K; Nishimura T
Urology; 2004 Sep; 64(3):589-90. PubMed ID: 15351603
[TBL] [Abstract][Full Text] [Related]
9. Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?
Daskivich TJ; Oh WK
Urology; 2006 May; 67(5):1084.e15-7. PubMed ID: 16698377
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
11. Granulomas induced by subcutaneous injection of leuprorelin acetate.
Sakamoto R; Higashi Y; Mera K; Kanekura T; Kanzaki T
J Dermatol; 2006 Jan; 33(1):43-5. PubMed ID: 16469084
[TBL] [Abstract][Full Text] [Related]
12. Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer.
Boccon-Gibod L; Iversen P; Persson BE
Expert Rev Anticancer Ther; 2009 Dec; 9(12):1737-43. PubMed ID: 19954284
[TBL] [Abstract][Full Text] [Related]
13. Pituitary apoplexy after leuprolide.
Davis A; Goel S; Picolos M; Wang M; Lavis V
Pituitary; 2006; 9(3):263-5. PubMed ID: 16832587
[TBL] [Abstract][Full Text] [Related]
14. Localized amyloidosis of the seminal vesicle. Possible association with hormonally treated prostatic adenocarcinoma.
Unger PD; Wang Q; Gordon RE; Stock R; Stone N
Arch Pathol Lab Med; 1997 Dec; 121(12):1265-8. PubMed ID: 9431316
[TBL] [Abstract][Full Text] [Related]
15. [Prostatic cancer with cystic formation: a case report].
Kubo M; Taguchi K; Fujisue H; Ihara H; Ikoma F
Hinyokika Kiyo; 1998 Dec; 44(12):883-6. PubMed ID: 10028435
[TBL] [Abstract][Full Text] [Related]
16. Pituitary apoplexy induced by Gonadotropin-releasing hormone agonists for treating prostate cancer-report of first Asian case.
Huang TY; Lin JP; Lieu AS; Chen YT; Chen HS; Jang MY; Shen JT; Wu WJ; Huang SP; Juan YS
World J Surg Oncol; 2013 Oct; 11():254. PubMed ID: 24088191
[TBL] [Abstract][Full Text] [Related]
17. Unexpected enlargement of clinically silent pituitary gonadotroph adenoma induced by goserelin acetate given as treatment for prostate cancer.
Ito Y
Int J Urol; 2011 Jan; 18(1):83-4. PubMed ID: 21077963
[No Abstract] [Full Text] [Related]
18. [Two cases of non-functional gonadotroph adenoma pituitary apoplexy following GnRH-agonist treatment revealing gonadotroph adenoma and pseudopituitary apoplexy after GnRH administration].
Hernandez Morin N; Huet D; Hautecouverture M
Ann Endocrinol (Paris); 2003 Jun; 64(3):227-31. PubMed ID: 12910066
[TBL] [Abstract][Full Text] [Related]
19. Pituitary apoplexy after leuprolide administration for carcinoma of the prostate.
Morsi A; Jamal S; Silverberg JD
Clin Endocrinol (Oxf); 1996 Jan; 44(1):121-4. PubMed ID: 8706284
[TBL] [Abstract][Full Text] [Related]
20. Gn-RH antagonist possible response, after Gn-RH agonist failure in a man with metastatic prostate cancer.
Rocco B; Ferrari M; Scardino E; Matei DV; Verweij F; Varela R; De Cobelli O
Anticancer Res; 2005; 25(1B):577-8. PubMed ID: 15816630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
